Clinical Trials Logo
NCT number NCT03497845
Study type Interventional
Source Biomedical Advanced Research and Development Authority
Contact Angela Greer
Phone 615-707-0176
Email Angela.Greer@ppdi.com
Status Recruiting
Phase Phase 2
Start date March 15, 2018
Completion date September 2, 2019

Clinical Trial Summary

The main purpose of this study is to assess the ability of H5 influenza virus vaccines and adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to generate an immune response to homologous and to antigenically distant heterologous H5 influenza virus strains.

The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms